Gain Therapeutics to Participate at H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024 07:00 ET
|
Gain Therapeutics, Inc.
BETHESDA, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of...
Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease
August 29, 2024 07:30 ET
|
Gain Therapeutics, Inc.
Results Include Safety, Tolerability, Pharmacokinetics, and Target Engagement GT-02287, in Development for GBA1 Parkinson’s Disease, on Track to Initiate Phase 1b Trial in Patients in Q4 2024 ...
Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update
August 08, 2024 07:30 ET
|
Gain Therapeutics, Inc.
Topline Results From MAD Phase 1 Study of GT-02287 on Track for August 2024 With Full Presentation at Upcoming Medical Conferences in Early Q4 2024 Initiation of Phase 1b Study of GT-02287 in...
Gain Therapeutics to Participate at BTIG Virtual Biotechnology Conference
August 01, 2024 08:00 ET
|
Gain Therapeutics, Inc.
BETHESDA, Md. , Aug. 01, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of...
Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024
June 28, 2024 16:39 ET
|
Gain Therapeutics, Inc.
BETHESDA, Md., June 28, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of...
Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO
June 27, 2024 16:08 ET
|
Gain Therapeutics, Inc.
Mr. Mack is the Company’s Current CFO Khalid Islam, PhD, Founder and Chairman of the Board, to serve as Executive Chairman BETHESDA, Md., June 27, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics,...
Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease
June 27, 2024 08:35 ET
|
Gain Therapeutics, Inc.
BETHESDA, Md., June 27, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of...
Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
June 25, 2024 07:00 ET
|
Gain Therapeutics, Inc.
BETHESDA, Md., June 25, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of...
Gain Therapeutics Announces Pricing of $11.0 Million Public Offering
June 13, 2024 21:00 ET
|
Gain Therapeutics, Inc.
BETHESDA, Md., June 13, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain” or the “Company”) (Nasdaq: GANX) today announced the pricing of an underwritten public offering of (i) 7,116,547...
Gain Therapeutics Announces Proposed Public Offering
June 13, 2024 16:44 ET
|
Gain Therapeutics, Inc.
BETHESDA, Md., June 13, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain” or the “Company”) (Nasdaq: GANX) today announced that it is proposing to offer and sell, subject to market...